Menu Back to Metrics-for-Return-on-Engagement-in-Patient-Centered-Drug-Development-Conference


October 17: Short Course*
October 18-19: Conference

*Short Course requires separate registration.

As awareness and theory around patient-centric medical product development have matured, discussion about measuring the value of patient engagement, including quantification of return on engagement (ROE), has increased. A growing number of engagement approaches and methods are available for adoption and use, but there is little documentation of ways to measure their contribution to the desired outcomes of a therapeutic development program. Assessing the ROE of patient engagement efforts enables an understanding of this impact as well as how human and financial resources may be used most effectively to achieve the most important outcomes for all stakeholders. 

The medical products industry is at a critical juncture, with an opportunity to define medical product development operational activities and measures that will encourage and support the growth of patient centricity. This conference will examine the core principles of measuring the ROE of patient engagement and demonstrate how current and emerging approaches are being applied by industry colleagues to measure engagement impact on outcomes of importance to patient, industry, regulatory, and payer stakeholders. Lessons learned will provide a valuable resource for attendees addressing challenges and resolving problems in the design and implementation of their own patient-centric initiatives and ROE measures.

Who should attend?

Biopharmaceutical and Medical Device Professionals involved in:

  • Patient Advocacy/Engagement/Experience/Access (Including Chief Patient Officers)
  • Patient Communications
  • Medical Affairs and Medical Communications (Including Chief Medical Officers)
  • Health Outcomes
  • Study Endpoint Development
  • Clinical Trial Design and Optimization
  • Clinical Research
  • Clinical Operations
  • Benefit-Risk Assessment
  • Pharmacovigilance and Risk Management
  • Medical Science Liaisons
  • C-Suite Executives, Global Heads, Senior Directors, and Other Decision-Makers

Patient Organizations
Regulatory Agency Reviewer and Decision-Makers

Learning objectives

At the conclusion of this conference, participants should be able to:

  • Describe the current policy landscape for patient engagement in the medical product development life cycle and its impact on the needs of industry stakeholders in measuring engagement outcomes
  • Assess areas of commonality and divergence among key needs of patient, regulatory, industry, and payer stakeholders in the medical product life cycle as a basis for strategizing measures of return on engagement
  • Discuss how to apply current and emerging approaches to measurement of engagement outcomes and ROE
  • Assimilate lessons learned on “what worked” for early adopters in order to anticipate potential challenges and optimize outcomes and ROE

Program Committee

  • Marc M. Boutin, JD
    Marc M. Boutin, JD Chief Executive Officer
    National Health Council (NHC), United States
  • Ellen  Coleman
    Ellen Coleman Senior Vice President
    Mark Krueger and Associates, Inc., United States
  • Kenneth A. Getz, MBA
    Kenneth A. Getz, MBA Director of Sponsored Research Programs and Associate Professor
    Center For the Study of Drug Development, Tufts University School of Medicine, United States
  • Elizabeth  Lincoln, MA
    Elizabeth Lincoln, MA Global Director of Engagement
    DIA, United States
  • K. Kimberly  McCleary
    K. Kimberly McCleary Managing Director
    FasterCures, A Center of the Milken Institute, United States
  • Roslyn F Schneider
    Roslyn F Schneider Global Patient Affairs Lead
    Pfizer Inc., United States
  • Suzanne  Schrandt, JD
    Suzanne Schrandt, JD Director, Patient Engagement
    Arthritis Foundation, United States
Load More

Contact us

Registration Questions?

Send Email

Digital Learning Catalog

eLearning Catalog Cover